Scientific scouting doesn’t fail because of missing data.

It fails because it is extremely hard to identify signal fast enough to influence real decisions.

In this masterclass, Arne Smolders (Founder & CEO of AcademicLabs) walks through **practical, repeatable and easy workflows **used by pharma, biotech, consultants, and investors to find & evaluate experts, startups, partners, technologies, IP, assets, targets and trials - at scale - in minutes.

No theory. No hype. Just 12 real decision workflows. Each 4-8 minutes.

Who got most value from this so far?

• External Innovation, Technology Scouting and Search & Evaluation teams
• Scientific Intelligence & Early Competitive Intelligence
• Business Development & Licensing and Strategy
• Pharma Discovery / Preclinical / Clinical Development
• Biotech Founders, BD and R&D
• Biotech/Pharma Consultants
• Life Science Investor Analysts and Venture Builders
• Researchers

What use cases are covered?

1. KOL Fit: Rank top 50 experts based on current scientific signal, not reputation or visibility
2. Rising Star Fit: Identify the next generation of leaders before they become obvious
3. Collaboration Potential: Evaluate 100s of academic research groups for real collaboration fit
4. Startup In-Licensing: Assess startup technologies, assets, validation, and strategic fit at scale
5. Startup/Competitor Tracking: Instantly see what changed across dozens or hundreds of M&A / In-Licensing / Partnering candidates you track
6. Technology Landscapes: Map where real innovation is emerging (e.g. ADCs, delivery, platforms)
7. Rapid FTO Prescreening: Reduce patent noise by ~90% in minutes before involving IP counsel
8. First-in-Class Technologies: Detect early, high-impact innovations via across all newly funded projects
9. Early-Stage Assets: Surface promising drugs and approaches from publications, projects & labs
10. Late-Stage Assets: Landscape clinical assets, trials, and competitors with evidence
11. Novel Targets: Identify emerging, credible targets with early biological validation
12. Clinical Trial Design: Easily identify smarter endpoints, biomarkers, and designs to create advantage

Can I do such an analysis on my topic too?

Yes! Afterwards, you can run any or multiple of such analyses yourself, as you will receive:

• 3 days free access
• 1000 free/extra AI credits
• all queries used
• all AI prompts used
• all Analysis Outcomes

FAQs

Q1: How fast are these workflows compared to traditional scouting?

What typically takes days or weeks of manual review can be done in minutes, including ranking and prioritization.

Q2: How many researchers or companies can be evaluated at once?

Depending on the workflow, teams evaluate 50, 200, or up to 2,000+ profiles (researchers, groups, startups, companies) or documents (publications, patents, funded projects, clinical trials, news, academic programs) in a single run - in seconds to minutes.

Q3: Does speed come at the cost of depth?

No. Speed comes from automation and infrastructure, while depth is preserved through linked data, explicit criteria, scoring, and evidence-backed justifications.

Q4: How quickly can teams go from a broad landscape to a shortlist?

Teams typically move from thousands of candidates to a ranked shortlist in under 30 minutes, including review time.

Q5: Is this suitable for enterprise-scale scouting programs?

Yes. The workflows are designed for portfolio-level scouting, ecosystem mapping, and large-scale landscaping, not just one-off analyses.

Q6: What is the main bottleneck after running these workflows?

Human decision-making - reviewing the top-ranked candidates with tailored reports - rather than data collection or screening.

Q7: Can these workflows be applied to any disease or technology?

Yes. All examples are disease- and modality-agnostic. The same approach works for immunology, oncology, delivery technologies, diagnostics, devices, and even beyond life sciences.

Q8: Is this only useful for early-stage innovation?

No. The masterclass covers early discovery, translational research, in-licensing, and late-stage clinical assets, including trial design and competitive landscapes.

Q9: Can I pressure-test this on a real use case?

Yes. The workflows can be applied directly to your own disease area, technology, or partnering question. You can try it for free with AI credits - or reach out to Arne for tailored guidance.

Q10: Is this relevant beyond pharma?

Yes. Biotech, consulting, investors, academic tech transfer teams, and other R&D-intensive organizations use the same approaches.